BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law BREAKING FDA UPDATE MASSIVE FOR PEPTIDES The U.S. Food & Drug Administration is reportedly reclassifying 14 peptides from Category 2 ( compounding only, no legal prescribing) into Category 1. This means The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 (Body Protection Compound 157) Peptide for Tissue Repair & R ELITE BIO COMPOUNDS